<DOC>
	<DOCNO>NCT01426269</DOCNO>
	<brief_summary>The purpose study ass relapse , efficacy safety subject rosacea long-term treatment either Oracea® placebo , initial 12-week regimen Oracea® MetroGel® 1 % .</brief_summary>
	<brief_title>Evaluation Relapse , Efficacy Safety Long-term Treatment With Oracea® v Placebo</brief_title>
	<detailed_description>Adult subject moderate severe papulopustular rosacea receive Oracea® MetroGel® 1 % daily phase 1 ( baseline week 12 ) study . Subjects eligible enter phase 2 study base upon improvement Investigator 's Global Assessment ( IGA ) score . During phase 2 , subject receive either Oracea® placebo daily additional 40 week . Subjects relapse phase 2 discontinue study .</detailed_description>
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>Subject male female age 18 80 year inclusive . Subject papulopustular rosacea ( 11 40 papule pustule ) IGA moderate severe . For subject use medication treat concurrent medical condition , type dose must stable least 90 day prior study entry . Female subject pregnant , nurse plan pregnancy study . Subject active dermatological condition face may interfere conduct study . Subject use recently use medication may interfere absorption , distribution , elimination study medication , may interfere assessment efficacy safety study medication . Subject know allergy component study product , and/or know hypersensitivity tetracycline metronidazole .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>